Kyber’s Data Intelligence System Now Powered by New, Expanded Dataset

The most actionable ML-ready dataset, now even bigger and more granular, for investors seeking alpha in biotech

Investors using healthcare claims data have a distinct advantage -- and especially those using Kyber’s data. Now, our data intelligence system is powered by an even larger dataset.

Over the past year, we’ve enriched our offerings with a new, unified data feed -- engineered from the ground up with best-in-class deduplication, enrichment, quality control, and tokenization processes. It brings together our existing Rx claims source and adds new hard-to-find datasets that make the pharmacy claims 4x larger, including net-new specialty pharmacy drug names not available today.

This is a fundamentally stronger, more comprehensive data asset -- and a meaningful head start in identifying the alpha opportunities that come with access to drug names and claims volumes that other data vendors simply don’t have yet.

Most vendors give you data. Kyber gives you a system.

That's not a tagline. It's the honest answer to the question we get asked constantly: "How are you different from the other claims data vendors?"

Raw claims feeds require months of cleaning, modeling, and validation before they're usable. By the time most teams are ready to act, the signal has moved. Kyber's data intelligence system is built to compress that timeline — so you're moving earlier in the quarter, on cleaner signal, with more confidence.

With the development of this powerful dataset, Kyber’s data intelligence system becomes even more valuable. It includes:

• 500+ drugs, diagnostics & devices -- with ticker mapping across the universe of healthcare products
• 400+ backtested revenue forecasting models -- built and validated by our data science team
• 100s of KPIs, for easy ingestion of key utilization metrics
• Continuous access to our research analysts to support revenue estimates & custom models

The best healthcare data intelligence system for Wall Street is now powered by the biggest and most granular dataset.

We're also the only healthcare data science team focused exclusively on healthcare for Wall Street. That's the reason our models are built differently, our KPIs are built for revenue, and our analysts speak your language.

We built Kyber around four things that matter to investors:

• Accuracy — Predict growth with backtesting and forecasting models. 80% hit rate across 400+ validated products.
• Speed — Forecast performance earlier in the quarter with Week-6 ML signals, so you can move before the market does.
• Volume — Scale tracking across a larger universe of therapies to surface alpha you'd otherwise miss.
• Transparency — Clarity into KPIs and model performance drivers. Not a black box.

Flexible data delivery, built for how you actually work:

• Transaction-level data for deep-dive analysis
• KPI aggregated data & dashboards for portfolio monitoring
• ML-ready KPI data and revenue model outputs for systematic strategies

We’ve done the grueling, meticulous work for you -- data sourcing, cleaning, enrichment, model-building, legal & compliance.

For systematic quants specifically: we've shaved a year off your build timeline. Clean, ML-ready datafiles, ready to plug in.

We built Kyber to be the best data partner serving Wall Street. This is us delivering.